Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing Advaccine Raises $4.3 Million for Coronavirus Vaccine Development

publication date: Feb 11, 2020

Beijing Advaccine Biotechnology raised $4.3 million in a new funding that will be used to test a coronavirus (2019-nCoV) vaccine. Two weeks ago, Advaccine and Inovio of the US announced a partnership to develop a coronavirus vaccine, with Inovio receiving a $9 million grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to underwrite the work. Advaccine will be in charge of Phase I China testing that will parallel Inovio's. Advaccine expects to complete China preclinical development of the vaccine in 4 to 6 months and then apply for clinical testing approval. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital